A straightforward urine test might revolutionize the treatment of prostate cancer by diagnosing aggressive disease types up to five years sooner than conventional clinical methods.
The experimental test, called ‘PUR’ (Prostate Urine Risk), also recognizes males who within five years of diagnosis are up to eight times less likely to need therapy.
The most commonly used prostate cancer test includes taking a blood sample and measuring PSA (prostate-specific antigen) protein levels. Other exams include a physical examination known as Digital Rectal Examination(DRE), an MRI scan, or a biopsy.
Unfortunately, we are presently lacking the capacity to say which people with prostate cancer will need radical therapy and which of them will not.
The’ PUR’ (Prostate Urine Risk) experimental test used AI (artificial intelligence) to examine gene expression in 537 men gathered samples. By examining the cell-free expression of 167 genes, machine learning recognized 35 distinct mathematical combinations to generate the PUR risk signatures.
Previous urine tests were specifically intended for single purposes, such as re-biopsy detection of prostate cancer, known as a PCA3 test. But this recent one utilizes four PUR signatures to provide a concurrent evaluation of — low, intermediate and high— non-cancerous tissue and risk groups to demonstrate how aggressive the cancer is.